Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Nasopharyngeal Carcinoma 2Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Cancer Metastatic 1Nasopharyngeal Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Breast Neoplasms 1Biliary Tract Neoplasms 1Advanced Renal Cell Carcinoma (RCC) 1Advanced Malignant Solid Tumors 1Advanced Lung Cancer 1Advanced Breast Cancer 1

Interventions

Carboplatin 11atezolizumab 10Etoposide 9durvalumab 6Topotecan 6PM 01183 6Specimen Handling 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Irinotecan 2Injections 2Drug Therapy 2Cisplatin 2Biopsy 2AMG 757 2tremelimumab 1trastuzumab deruxtecan 1toripalimab 1olaparib 1lenvatinib 1fludarabine 1enzalutamide 1cabozantinib 1berzosertib 1avelumab 1arginine decarboxylase 1amrubicin 1Vaccines 1Taxes 1Sodium Chloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × toripalimab × 30 days × Clear all
NCT07559929 2026-05-29

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.

Hangzhou DAC Biotechnology Co., Ltd.

Phase 1/2 Not yet recruiting
200 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡